75 related articles for article (PubMed ID: 1649294)
1. Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor.
Trapani AJ; Smits GJ; McGraw DE; McMahon EG; Blaine EH
J Pharmacol Exp Ther; 1991 Jul; 258(1):269-74. PubMed ID: 1649294
[TBL] [Abstract][Full Text] [Related]
2. Depressor and natriuretic effects of M&B 22,948, a guanosine cyclic 3',5'-monophosphate-selective phosphodiesterase inhibitor.
McMahon EG; Palomo MA; Mehta P; Olins GM
J Pharmacol Exp Ther; 1989 Dec; 251(3):1000-5. PubMed ID: 2557409
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the inhibitory effect of N(G)-nitro-L-arginine methyl ester on the antihypertensive effect of the angiotensin AT1 receptor antagonist, GR138950.
Anderson IK; Drew GM
Br J Pharmacol; 1997 Dec; 122(7):1385-94. PubMed ID: 9421286
[TBL] [Abstract][Full Text] [Related]
4. Differential hemodynamic responses to selective inhibitors of cyclic nucleotide phosphodiesterases in conscious rats.
Dundore RL; Habeeb PG; Pratt PF; Becker LT; Clas DM; Buchholz RA
J Cardiovasc Pharmacol; 1992 Jun; 19(6):937-44. PubMed ID: 1376816
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular effects of rat calcitonin gene-related peptide in the conscious rat.
Sirén AL; Feuerstein G
J Pharmacol Exp Ther; 1988 Oct; 247(1):69-78. PubMed ID: 2459371
[TBL] [Abstract][Full Text] [Related]
6. N omega-nitro-L-arginine attenuates the accumulation of aortic cyclic GMP and the hypotension produced by zaprinast.
Dundore RL; Pratt PF; O'Connor B; Buchholz RA; Pagani ED
Eur J Pharmacol; 1991 Jul; 200(1):83-7. PubMed ID: 1663042
[TBL] [Abstract][Full Text] [Related]
7. Increased activity of guanosine 3'-5'-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites.
Angeli P; Jiménez W; Veggian R; Fasolato S; Volpin R; MacHenzie HS; Craighero R; Libera VD; Sticca A; Arroyo V; Gatta A
Hepatology; 2000 Feb; 31(2):304-10. PubMed ID: 10655250
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle.
Harris AL; Lemp BM; Bentley RG; Perrone MH; Hamel LT; Silver PJ
J Pharmacol Exp Ther; 1989 May; 249(2):394-400. PubMed ID: 2566675
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor.
Merkel LA; Rivera LM; Perrone MH; Lappe RW
Eur J Pharmacol; 1992 May; 216(1):29-35. PubMed ID: 1326438
[TBL] [Abstract][Full Text] [Related]
10. Analysis of vasodilator responses to peroxynitrite in the hindlimb vascular bed of the cat.
Nossaman BD; Bivalacqua TJ; Champion HC; Baber SR; Kadowitz PJ
J Cardiovasc Pharmacol; 2007 Oct; 50(4):358-66. PubMed ID: 18049302
[TBL] [Abstract][Full Text] [Related]
11. Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats.
Gardiner SM; Kemp PA; Brunner-Ferber F; Bennett T
Br J Pharmacol; 1997 Dec; 122(8):1687-93. PubMed ID: 9422815
[TBL] [Abstract][Full Text] [Related]
12. Systemic, pulmonary and coronary haemodynamic actions of the novel dopamine receptor agonist in awake pigs at rest and during treadmill exercise Z1046.
Duncker DJ; Haitsma DB; van der Geest IE; Stubenitsky R; van Meegen JR; Man in't Veld AJ; Verdouw PD
Br J Pharmacol; 1997 Mar; 120(6):1101-13. PubMed ID: 9134223
[TBL] [Abstract][Full Text] [Related]
13. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide.
Thusu KG; Morin FC; Russell JA; Steinhorn RH
Am J Respir Crit Care Med; 1995 Nov; 152(5 Pt 1):1605-10. PubMed ID: 7582302
[TBL] [Abstract][Full Text] [Related]
14. Regional hemodynamic effects of purinergic P2 receptor subtype agonists in rats.
Cox BF; Smits GJ
J Pharmacol Exp Ther; 1996 Jun; 277(3):1492-500. PubMed ID: 8667215
[TBL] [Abstract][Full Text] [Related]
15. Functional interaction of a beta-adrenergic agonist and cyclic GMP phosphodiesterase inhibitor in control and hypertrophic cardiomyocytes.
Zhang S; Rodriguez R; Scholz PM; Weiss HR
Pharmacology; 2006; 76(2):53-60. PubMed ID: 16276122
[TBL] [Abstract][Full Text] [Related]
16. Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts.
Weiss HR; Rodriguez E; Tse J; Scholz PM
Clin Exp Pharmacol Physiol; 1994 Aug; 21(8):607-14. PubMed ID: 7813120
[TBL] [Abstract][Full Text] [Related]
17. Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors.
Sugita M; Black KL
Cancer Res; 1998 Mar; 58(5):914-20. PubMed ID: 9500450
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3',5'-cyclic monophosphate degradation.
Wilkins MR; Settle SL; Needleman P
J Clin Invest; 1990 Apr; 85(4):1274-9. PubMed ID: 2156897
[TBL] [Abstract][Full Text] [Related]
19. Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits.
Holbrook M; Coker SJ
Br J Pharmacol; 1991 Aug; 103(4):1973-9. PubMed ID: 1655149
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular responses to the stimulation of alpha-1 and alpha-2 adrenoceptors in the conscious dog.
Woodman OL; Vatner SF
J Pharmacol Exp Ther; 1986 Apr; 237(1):86-91. PubMed ID: 2870177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
